MARKET

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.160
+0.260
+13.68%
Pre Market: 2.180 +0.02 +0.93% 05:06 09/22 EDT
OPEN
1.930
PREV CLOSE
1.900
HIGH
2.530
LOW
1.840
VOLUME
100
TURNOVER
--
52 WEEK HIGH
6.60
52 WEEK LOW
0.5603
MARKET CAP
221.00M
P/E (TTM)
-3.6948
1D
5D
1M
3M
1Y
5Y
Seelos Therapeutics Shares Gain On FDA Approval To Add SLS-005 Regimen In HEALEY ALS Trial
Benzinga · 13h ago
Why Seelos Therapeutics' Stock Is Trading Higher Today
Seelos Therapeutics (NASDAQ:SEEL) shares are trading higher. Traders are circulating a Massachusetts General Hospital report titled 'Investigational drug SLS-005 (Trehalose) receives "May Proceed" notice and Central IRB approval for the HEALEY ALS Platform...
Benzinga · 15h ago
Seelos Therapeutics Shares Spike Higher; Traders Circulate Massachusetts General Hospital Report Titled 'Investigational drug SLS-005 (Trehalose) receives "May Proceed" notice and Central IRB approval for the HEALEY ALS Platform Trial'
https://www.massgeneral.org/news/press-release/Investigational-drug-receives-may-proceed-notice-for-healey-als-trial
Benzinga · 16h ago
WAVE Life Sciences, Seelos Therapeutics Shares Up ~11% Following Earlier STAT News Article 'Facing pressure from ALS patients and advocates, the FDA does about-face on review of potential treatment'
https://www.statnews.com/2021/09/15/facing-pressure-from-als-patients-and-advocates-the-fda-does-about-face-on-review-of-potential-treatment/
Benzinga · 6d ago
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate leaders, working to create new methods for the treatment of mental health and other ser...
Benzinga · 09/09 20:46
Seelos Therapeutics to Participate in Two Investor Conferences in September
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the M-Vest Adva...
PR Newswire - PRF · 09/09 12:01
3 Psychedelic Stocks Wall Street Predicts Will Double or Triple
StockNews.com · 09/09 11:59
BRIEF-Seelos Therapeutics Appoints Margaret Dalesandro To Board Of Directors
reuters.com · 09/02 12:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SEEL. Analyze the recent business situations of Seelos Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SEEL stock price target is 8.58 with a high estimate of 14.00 and a low estimate of 2.500.
EPS
Institutional Holdings
Institutions: 120
Institutional Holdings: 41.09M
% Owned: 40.16%
Shares Outstanding: 102.32M
TypeInstitutionsShares
Increased
26
16.21M
New
51
8.45M
Decreased
19
5.48M
Sold Out
17
3.35M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.40%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/President/Chief Executive Officer/Director
Raj Mehra
Chief Financial Officer
Michael Golembiewski
Other
Anthony Marciano
Director
Margaret Dalesandro
Director
Richard Pascoe
Independent Director
Brian Lian
Independent Director
Daniel O'Connor
No Data
About SEEL
Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).

Webull offers kinds of Seelos Therapeutics Inc stock information, including NASDAQ:SEEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SEEL stock methods without spending real money on the virtual paper trading platform.